Floatz logo

65 assets in Gastric Adenocarcinoma

Therapeutic assets addressing Gastric Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Fluorouracilum
Gastric Adenocarcinoma
Boehringer IngelheimP3BB (66)
Capecitabine
Gastric Adenocarcinoma
Shanghai Zhongshan HospitalP3BB (65)
Trastuzumab
Gastric Adenocarcinoma
Boehringer IngelheimP2BB (65)
Oxaliplatin
Gastric Adenocarcinoma
Shanghai Zhongshan HospitalP3BB (64)
Pembrolizumab
Gastric Adenocarcinoma
EpkinP3BB (64)
Durvalumab
Gastric Adenocarcinoma
University of California, IrvineP2B (60)
Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer
Gastric Adenocarcinoma
University of California, IrvineP2B (60)
Irinotecan
Gastric Adenocarcinoma
Georgetown UniversityP3B (60)
Nivolumab
Gastric Adenocarcinoma
National University Hospital, SingaporeP2B (59)
Docetaxel
Gastric Adenocarcinoma
Kyowa Kirin Co., Ltd.P1/2B (58)
Atezolizumab
Gastric Adenocarcinoma
National University Hospital, SingaporeP3B (57)
Sargramostim
Gastric Adenocarcinoma
Mayo ClinicP1/2B (57)
Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, Dimer
Gastric Adenocarcinoma
Astellas Pharma Global Development, Inc.P1/2CCC (55)
Trastuzumab Deruxtecan
Gastric Adenocarcinoma
National Cancer Institute (NCI)P1/2CCC (54)
Olanzapine
Gastric Adenocarcinoma
OHSU Knight Cancer InstituteP2CCC (53)
Rain-32
Gastric Adenocarcinoma
Rain Oncology IncP2CCC (53)
Talazoparib
Gastric Adenocarcinoma
National Cancer Institute (NCI)P2CCC (53)
Tislelizumab
Gastric Adenocarcinoma
SOLTI Breast Cancer Research GroupP2CCC (53)
Utidelone
Gastric Adenocarcinoma
Beijing Biostar Pharmaceuticals Co., Ltd.P2CCC (53)
Adebrelimab
Gastric Adenocarcinoma
Shanghai Zhongshan HospitalP2CCC (51)
Adenovirus 5/F35-Human Guanylyl Cyclase C-Padre
Gastric Adenocarcinoma
Thomas Jefferson UniversityP2CCC (51)
Dostarlimab
Gastric Adenocarcinoma
UNICANCERP2CCC (51)
Human Adenovirus C Serotype 5
Gastric Adenocarcinoma
Thomas Jefferson UniversityP2CCC (51)
Metformin
Gastric Adenocarcinoma
Dan ZandbergP2CCC (51)
Rosiglitazone
Gastric Adenocarcinoma
Dan ZandbergP2CCC (51)
Shr-8068
Gastric Adenocarcinoma
Shanghai Zhongshan HospitalP2CCC (51)
Tucatinib
Gastric Adenocarcinoma
Seagen, a wholly owned subsidiary of PfizerP2CCC (51)
Spartalizumab
Gastric Adenocarcinoma
SOLTI Breast Cancer Research GroupP2CCC (48)
bi-1607
Gastric Adenocarcinoma
BioInvent International ABP1/2CC (47)
Cyclophosphamide
Gastric Adenocarcinoma
Beijing BiotechP1/2CC (47)
Dual-Target Car-Nk Cells
Gastric Adenocarcinoma
Beijing BiotechP1/2CC (47)
Fludarabine
Gastric Adenocarcinoma
Beijing BiotechP1/2CC (47)
Trastuzumab Emtansine
Gastric Adenocarcinoma
Boehringer IngelheimP1/2CC (47)
Zanidatamab
Gastric Adenocarcinoma
Boehringer IngelheimP1/2CC (47)
Zongertinib
Gastric Adenocarcinoma
Boehringer IngelheimP1/2CC (47)
Apl-5125
Gastric Adenocarcinoma
Apollo Therapeutics LtdP1/2CC (43)
Azenosertib
Gastric Adenocarcinoma
National Cancer Institute (NCI)P1CC (43)
bhb810
Gastric Adenocarcinoma
BigHat Biosciences, Inc.P1/2CC (43)
ct041 autologous car t-cell
Gastric Adenocarcinoma
CARsgen Therapeutics Co., Ltd.P1/2CC (43)
jk08
Gastric Adenocarcinoma
Salubris Biotherapeutics IncP1/2CC (43)
Lenvatinib
Gastric Adenocarcinoma
Salubris Biotherapeutics IncP1/2CC (43)
nm32-2668
Gastric Adenocarcinoma
Numab Therapeutics AGP1CC (43)
okn4395
Gastric Adenocarcinoma
EpkinP1CC (43)
Rivoceranib
Gastric Adenocarcinoma
CARsgen Therapeutics Co., Ltd.P1/2CC (43)
Sacituzumab Tirumotecan
Gastric Adenocarcinoma
Klus Pharma Inc.P1/2CC (43)
Sonidegib
Gastric Adenocarcinoma
Mayo ClinicP1CC (43)
Tipiracil
Gastric Adenocarcinoma
Emory UniversityP1/2CC (43)
Trifluridine
Gastric Adenocarcinoma
Emory UniversityP1/2CC (43)
Sigvotatug Vedotin
Gastric Adenocarcinoma
Seagen, a wholly owned subsidiary of PfizerP1CC (42)
Ropidoxuridine
Gastric Adenocarcinoma
National Cancer Institute (NCI)P1CC (41)
Showing 1 to 50 of 65 assets
PreviousPage 1 of 2Next